Lexicon Pharmaceuticals Stock Rises Nearly 6% After Analyst Initiates Coverage
On Monday, Lexicon Pharmaceuticals (NASDAQ: LXRX) saw its stock rise by nearly 6%, driven by a bullish initiation of coverage from Cantor Fitzgerald analyst Steve Seedhouse. He rated the stock as an overweight with a price target of $8 per share—more than four times its current level of around $1.90. Seedhouse highlighted Lexicon's progress in developing sotagliflozin, which is already FDA-approved for treating heart failure and related risks under the brand name Inpefa. The drug is now being tested for additional indications such as hypertrophic cardiomyopathy (HCM). Seedhouse noted that if approved for HCM, it could complement rather than compete with existing treatments due to its unique mechanism of action. Despite this positive outlook, analysts caution that no drug approval is guaranteed and Lexicon remains a high-risk investment typical of small pharmaceutical companies. The stock's recent performance reflects investor optimism about the company’s pipeline potential.
Topics: clinical trials FDA approval process Lexicon Pharmaceuticals stock price movement